Surgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1

Clinics

Volumn 67, Issue SUPPLEMENT, 2012, Pages 173-178

  Åkerström, Göran ^a   Stålberg, Peter ^a   Hellman, Per ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Multiple Endocrine Neoplasia Type 1; Neuroendocrine Pancreatico Duodenal Tumors; Surgical Treatment

Indexed keywords

DUODENUM TUMOR; GENETICS; HUMAN; LIVER TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; PANCREAS TUMOR; PATHOLOGY; REVIEW;

DUODENAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PANCREATIC NEOPLASMS;

EID: 84863941021     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(Sup01)29     Document Type: Review

References (64)

1. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med. 1954;16(3):363-71.
2. Skogseid B, Rastad J, Åkerström G. Pancreatic endocrine tumors in multiple endocrine neoplasia type I. In: Doherty GM, Skogseid B, editorsSurgical Endocrinology. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001;pp.511-24
3. Åkerström G, Hessman O, Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbeck's Arch Surg. 2002;386(8):558-69.
4. Beckers A, Abs R, Willems PJ, van der Auwera B, Kovacs K, Reznik M, et al. Aldosterone-secreting adrenal adenoma as part of the multiple endocrine neoplasia type 1 (MEN 1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN 1 locus. J Clin Endocrinol Metab. 1992;75(2):564-70.
5. Teh BT, Zedenius J, Kytölä S, Skogseid B, Trotter J, Choplin H, et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg. 1998;228(1):99-105.
6. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404-7.
7. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN 1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008;29(1):22-32.
8. Tham E, Grandell U, Lindgren E, Toss G, Skogseid B, Nordenskjöld M. Clinical testing for mutations in the MEN 1 gene in Sweden: a report on 200 unrelated cases. J Clin Endocrinol Metab. 2007;92(9):3389-95.
9. Skogseid B, Eriksson B, Lundquist G, Lörelius LE, Rastad J, Wide L, et al. Multiple endocrine neoplasia type I: A 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab. 1991;73(2):281-87.
10. Lairmore TC, Piersall LD, DeBenedetti MK, Dilley WG, Mutch MG, Whelan AJ, et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg. 2004;239(5):637-45.
11. Åkerström G, Stålberg P. Surgical management of MEN-1 and-2: State of the art. Surg Clin N Am. 2009;89(5):1047-68.
12. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type1 and type2. J Clin Endocrinol Metab. 2001;86(12):5658-71.
13. Uchino S, Noguchi S, Sato M, Yamashita H, Yamashita H, Watanabe S, et al. Screening of the MEN 1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res. 2000;60(19):5553-57.
14. Langer P, Wild A, Hall A, Celik I, Rothmund M, Bartsch DK, et al. Prevalence of multiple endocrine neoplasia type 1 in young patients with apparently sporadic primary hyperparathyroidism or pancreaticoduodenal endocrine tumors. Br J Surg. 2003;90(12):1599-1603.
15. Burgess JR, David R, Greenway TM, Parameswaran V, Shepherd JJ. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg. 1999;134(10):1119-23.
16. Åkerström G, Juhlin C. Surgical management of multiglandular parathyroid disease. In: Randolph GW, editor. Surgery of the Thyroid and Parathyroid Glands. Philadelphia, PA: Saunders; 2003;pp. 529-48.
17. Norton JA, Venzon DJ, Berna MJ, Alexander HR, Fraker DL, Libutti SK, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg. 2008;247(3):501-10.
18. Åkerström G, Hessman O, Hellman P, Skogseid B. Pancreatic tumours as part of the MEN-I syndrome. Best Pract Res Clin Gastroenterol. 2005;19(5):819-30.
19. Lopez CL, Waldman J, Fendrich V, Langer P, Kann P, Bartsch DK. Longterm results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg. 2011;396(8):1187-96. DOI 10.1007/s00423-011-0828-1
20. Åkerström G, Johansson H, Grama G. Surgical treatment of endocrine pancreatic lesions in MEN-I. Acta Oncol. 1991;30(4):541-45.
21. Grama D, Skogseid B, Wilander E, Eriksson B, Mårtensson H, Cedermark B, et al. Pancreatic tumors in multiple endocrine neoplasia type I: clinical presentation and surgical treatment. World J Surg. 1992;16(4):611-19.
22. Klöppel G, Willemer S, Stamm B, Häcki WH, Heitz PU. Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I: an immunocytochemical study of nine patients. Cancer. 1986;57(9):1824-32.
23. Pipellers-Marichal M, Somers G, Willems E, Foulis A, Imrie C, Bishop AE, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type I and the Zollinger-Ellison syndrome. N Engl J Med. 1990;322(11):723-7.
24. Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006;30(5):643-53.
25. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14(23):7798-7803.
26. Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA Jr, Norton JA. Lethality of multiple endocrine neoplasia type I. World J Surg. 1998;22(6):581-7.
27. Dean PG, van Heerden JA, Farley DR, Thompson GB, Grant CS, Harmsen WS, et al. Are patients with multiple endocrine neoplasia type I prone to premature death? World J Surg. 2000;24(11):1437-41.
28. Lowney J, Frisella MM, Lairmore TC, Doherty GM. Islet cell tumor metastasis in multiple endocrine neoplasia type I: correlation with primary tumor size. Surgery. 1998;124(6):1043-9.
29. Skogseid B, öberg K, Eriksson B, Juhlin C, Granberg D, Akerström G et al. Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type I. World J Surg. 1996;20(7):872-7.
30. Thompson NW, Vinik AI, Eckhauser F. Microgastrinomas of the duodenum: A cause of failed operations for the Zollinger-Ellison syndrome. Ann Surg. 1989;168(4):396-404.
31. Thompson NW. Current concept in the surgical management of multiple endocrine neoplasia type 1 pancreaticoduodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med. 1998;243(6):495-500.
32. Skogseid B, öberg K, Åkerström G. Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization? World J Surg. 1998;22(6): 673-8.
33. Triponez F, Goudet P, Dosseh D, Cougard P, Bauters C, Murat A, et al. Is surgery beneficial for MEN 1 patients with small (#2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg. 2006;30(5):654-62.
34. Triponez F, Dosseh D, Goudet P, Cougard P, Bauters C, Murat A, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg. 2006;243(2):265-72.
35. Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, et al. Risk factors and causes of death in MEN 1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34(2):249-55.
36. Doherty GM, Thompson NW. Multiple endocrine neoplasia type 1: duodenopancreatic tumours. J Intern Med. 2003;253(6):590-8.
37. Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg. 2005;242(5):757-66.
38. 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 2005;90(6):3392-3400.
39. Hellman P, Hennings J, Åkerström G, Skogseid B. Endoscopic ultrasound for evaluation of pancreatic tumors in multiple endocrine neoplasia type 1. Br J Surg. 2005;92(12):1508-12.
40. O'Riordian DS, O'Brian T, van Heerden JA, Service FJ, Grant CS. Surgical management of insulinoma associated with multiple endocrine neoplasia type 1. World J Surg. 1994;18(4):488-94.
41. Demeure MJ, Klonoff CC, Karam JH, Demeure MJ. Insulinomas associated with multiple endocrine neoplasia type 1: the need for a different surgical approach. Surgery. 1991;110(3):998-1005.
42. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19:783-98.
43. Tonelli F, Fratini G, Falchetti A, Nesi G, Brandi ML. Surgery for gastroenteropancreatic tumors in multiple endocrine neoplasia type 1: review and personal experience. J Intern Med. 2005;257(1):38-49.
44. Bartsch D, Langer P, Wild A, Schilling T, Celik I, Rothmund M, et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: Surgery or surveillance? Surgery. 2000;128:958-66.
45. Levy-Bohbot N, Merie C, Goudet P, Delemer B, Calender A, Jolly D, et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas. Gastroenterol Clin Biol. 2004;28(11):1075-81.
46. Hellman P, Ladjevardi S, Skogseid B, Akerström G, Elvin A. Radiofrequency tissue ablation using coiled tip for liver metastases of endocrine tumors. World J Surg. 2002;26(8):1052-6.
47. Jensen RT. Carcinoid and endocrine pancreatic tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol. 2000;12(4):368-77.
48. Norton JA. Surgery and prognosis of duodenal gastrinoma as a duodenal neuroendocrine tumor. In: Arnold R, editor. Best Practice & Research: Clinical Gastroenterology. Elsevier. 2005;19(5):699-704.
49. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341(9):635-44.
50. Norton J, Jensen RT. Role of surgery in Zollinger-Ellison syndrome. J Am Coll Surg. 2007;205 suppl 4:S34-S37.
51. Åkerström G, Hellman P, StÅlberg P. Carcinoid: Presentation and diagnosis, surgical management. In: Hubbard JGH, Inabnet WB, Lo CY, editors. Endocrine Surgery (Springer Specialist Surgery Series). London: Springer-Verlag; 2008, Chapter 44.
52. Modlin IM, Lawton GP. Duodenal gastrinoma: the solution to the pancreatic paradox. J Clin Gastroenterol. 1994;19(3):184-8.
53. Hausman MSJr, Thompson NW, Gauger PG, Doherty GM. The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery. 2004;136(6):1205-11.
54. Gauger PG, Doherty GM, Broome JT, Miller BS, Thompson NW. Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery. 2009;146(4):801-6.
55. Tisell LE, Ahlman H, Jansson S, Grimelius L. Total pancreatectomy in the MEN 1 syndrome. Br J Surg. 1988;75(2):154-7.
56. Kato M, Imamura M, Hosotani R, Shimada Y, Doi R, Itami A, et al. Curative resection of microgastrinomas based on the intraoperative secretin test. World J Surg. 2000;24(11):1425-30.
57. Imamura M, Komoto I, Doi R, Onodera H, Kobayashi H, Kawai Y. New pancreas-preserving total duodenectomy technique. World J Surg. 2005;29(2):203-7.
58. Imamura M, Komoto I, Ota S, Hiratsuka T, Kosugi S, Doi R, et al. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol. 2011;17:1343-53.
59. Richards ML, Gauger P, Thompson NW, Giordano TJ. Regression of Type II gastric carcinoids. World J Surg. 2004;28(7):652-8.
60. Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004;136(6):1267-74.
61. Lairmore TC, Chen VY, DeBenedetti MK, Gillanders WE, Norton JA, Doherty GM. Duodenopancreatic resections in patients with multiple endocrine neoplasia type I. Ann Surg. 2000;231(6):909-18.
62. You YN, Thompson GB, Young WF, Larson D, Farley DR, Richards M, et al. Pancreatoduodenal surgery in patients with multiple endocrine neoplasia type 1: Operative outcomes, long-term function, and quality of life. Surgery. 2007;142(6):829-36.
63. Wilson SD, Krzywda EA, Zhu YR, Yen TW, Wang TS, Sugg SL, et al. The influence of surgery in MEN-1 syndrome: Observations over 150 years. Surgery. 2008;144(4):695-702.
64. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with the Zollinger-Ellison syndrome. Ann Surg. 2004;240(5):753-7.